Loading...
XASX
BLS
Market cap135mUSD
Nov 19, Last price  
0.83AUD
1D
3.01%
1Q
-8.06%
Jan 2017
578.57%
IPO
-45.89%
Name

Bioxyne Ltd

Chart & performance

D1W1MN
XASX:BLS chart
P/E
39.98
P/S
6.44
EPS
0.02
Vol. 1Y
75.55%
Shs. 5Y
-19.61%
Rev. 5Y
68.21%
Div Yld LY
—
Div Yld TTM
—
Revenues
30m
+226.27%
1,684,644837,092674,5631,147,695751,897939,644123,275880,4972,391,7301,645,2382,024,2172,054,2912,151,3752,202,2822,259,2642,110,377463,6365,160,5389,325,02030,424,500
Net income
5m
P
-1,877,981-1,726,025-1,331,146-210,90680,1441,054-1,784,131-6,191,1131,190,827201,039223,846-765,752-1,311,840-1,265,882-593,095-495,725-494,022-1,939,970-13,325,0504,901,181
CFO
6m
P
-2,263,179-1,355,177-1,089,640-491,478152,072-76,369-4,695,374-971,704606,757-166,772348,852-424,048-1,855,355-1,390,36248,24953,134-506,811-1,131,026-3,559,9546,276,527

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BLS Pharmaceuticals Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.

Key people

Anthony Ho
Chairman of the Board · since 2012
Samuel Watson
Chief Executive Officer, Managing Director, Director · since 2023
Chief Financial Officer, Chief Operating Officer, Company Secretary · since 2023
Jason Hine
Director · since 2023
IPO date
Dec 14, 2000
Employees
16
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT